EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Cost Effectiveness of Adjunctive Treatments for Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease

Ulysses S Rosas, Christopher V Almario, Kyung-Sang Yu, Brennan M R Spiegel

Clinical Drug Investigation · 2024

DOI: 10.1007/s40261-024-01387-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Drug Investigation, 2024. Verfasst von Ulysses S Rosas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Hauptthemen laut MEDLINE: Gastroesophageal Reflux, Proton Pump Inhibitors, Cost-Benefit Analysis, Markov Chains. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ironwood Pharmaceuticals, Incorporated, Cedars-Sinai Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Half of patients with gastroesophageal reflux disease (GERD) experience persistent symptoms while on proton pump inhibitors (PPIs), thus driving efforts to develop novel adjunctive therapies for PPI-refractory GERD. An economic analysis was performed to establish at what cost and efficacy such potential medications are likely to become cost effective in clinical practice. METHODS: A Markov decision model was used to examine a hypothetical cohort of patients being evaluated for PPI-refractory GERD in the USA. The model compared 3 strategies: (1) usual care (i.e., upfront diagnostic testing with upper endoscopy ± ambulatory pH testing); (2) use of a PPI-adjunctive therapy after positive ambulatory pH testing; and (3) empiric use of a PPI-adjunctive therapy (i.e., diagnostic testing only after failing empiric treatment). The primary outcome was incremental cost per quality-adjusted life year (QALY) gained (third-party payer perspective) over a 10-year time horizon using a willingness to pay threshold of $100,000/QALY. RESULTS: In two-way sensitivity analyses varying the cost and effectiveness of the PPI-adjunctive therapy, most combinations revealed that use of the medication after positive pH testing was the most cost-effective approach. Empiric treatment was the preferred strategy only when the therapy was highly efficacious (≥ 87.5% response rate) and low cost (≤ $109/month). Use of PPI-adjunctive treatments were not cost effective when the cost exceeded $1150/month. CONCLUSION: Use of PPI-adjunctive therapies in those with persistent GERD symptoms may become cost effective when guided by ambulatory pH tests. These data can guide investigators, industry, and payers as they develop, validate, and price new treatments for PPI-refractory GERD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastroesophageal RefluxProton Pump InhibitorsCost-Benefit AnalysisMarkov ChainsHumansQuality-Adjusted Life YearsModels, EconomicCost-Effectiveness Analysis

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Medicine and Public Health, Gourrich Chair in Digital Health Ethics, Cedars-Sinai Medical Center, Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), 116…
  • Division of Health Services Research, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Cedars-Sinai Center for Outcomes Research and Education (CS-CORE), Los Angeles, CA, USA.
  • Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA. brennan.spiegel@cshs.org.

Förderung

  • Ironwood Pharmaceuticals, Incorporated
  • Cedars-Sinai Medical Center

Zitieren

APA

Rosas, U. S., Almario, C. V., Yu, K. S., & Spiegel, B. M. R. (2024). The Cost Effectiveness of Adjunctive Treatments for Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Clinical Drug Investigation. https://doi.org/10.1007/s40261-024-01387-7

Vancouver

Rosas US, Almario CV, Yu KS, Spiegel BMR. The Cost Effectiveness of Adjunctive Treatments for Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Clinical Drug Investigation. 2024. doi:10.1007/s40261-024-01387-7

BibTeX
@article{Rosas2024,
  author = {Rosas, Ulysses S and Almario, Christopher V and Yu, Kyung-Sang and Spiegel, Brennan M R},
  title = {The Cost Effectiveness of Adjunctive Treatments for Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease},
  journal = {Clinical Drug Investigation},
  year = {2024},
  doi = {10.1007/s40261-024-01387-7}
}
Kostenlos starten →